High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy

International Journal of Cancer

Volumn 120, Issue 4, 2007, Pages 942-946

  Freier, Kolja ^a,b   Pungs, Susanne ^a   Sticht, Carsten ^a,b   Flechtenmacher, Christa ^a   Lichter, Peter ^b   Joos, Stefan ^b   Hofele, Christof ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BIRC5; Immunohistochemistry; Oral squamous cell carcinoma; Survivin; Tissue microarray analysis

Indexed keywords

SURVIVIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BIRC5 GENE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33846630796     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22380     Document Type: Article

References (35)

1. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001;49:72-82.
2. Tankere F, Camproux A, Barry B, Guedon C, Depondt J, Gehanno P. Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. Laryngoscope 2000;110:2061-5.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087-90.
6. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
7. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002;11:33-40.
8. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
9. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998;273:11177-82.
10. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, Procaccini M, Ferrari F, De Rosa G, Altieri DC. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003;89:2244-8.
11. Lin CY, Hung HC, Kuo RC, Chiang CP, Kuo MY. Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol 2005;41:645-54.
12. Weber RG, Scheer M, Born IA, Joos S, Cobbers JM, Hofele C, Reifenberger G, Zoller JE, Lichter P. Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am J Pathol 1998;153:295-303.
13. Wolff E, Girod S, Liehr T, Vorderwulbecke U, Ries J, Steininger H, Gebhart E. Oral squamous cell carcinomas are characterized by a rather uniform pattern of genomic imbalances detected by comparative genomic hybridisation. Oral Oncol 1998;34:186-90.
14. Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, Lichter P, Hofele C. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179-82.
15. Sticht C, Hofele C, Flechtenmacher C, Bosch FX, Freier K, Lichter P, Joos S. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2005;92:770-4.
16. Freier K, Bosch FX, Flechtenmacher C, Devens F, Benner A, Lichter P, Joos S, Hofele C. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res 2003;23:3971-7.
17. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003;88:1077-83.
18. Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, Solary E, Piard F. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005;131:504-10.
19. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003;29:379-82.
20. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, Shroyer KR. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Molecul Morphol 2002;10:134-8.
21. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27-33.
22. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22.
23. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-δEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
24. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-43.
25. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002;100:30-6.
26. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-7.
27. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 2005;138:299-305.
28. Kappler M, Taubert H, Bartel F, Blumke K, Panian M, Schmidt H, Dunst J, Bache M. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005;13:167-72.
29. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23:7494-506.
30. Warnecke-Eberz U, Hokita S, Xi H, Higashi H. Baldus SE, Metzger R, Brabender J, Bollschweiler E, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13:1241-6.
31. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86; discussion 86-7.
32. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004;64:3780-9.
33. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, Hii G, Winter C, Shahzad S, Asziz MU, Biegel JA, Weber BL, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403.
34. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, Tas E, Serra M, Tarkkanen M, Knuutila S. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 2005;42:158-63.
35. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.